Skip to content

Assessment of Functionality of Patients with Type IV Spinal Muscular Atrophy Treated with Spinraza: A Study with use of the Timed Up and Go Test, the Six-Minute Walk Test, the Hammersmith Functional Motor Scale, and Stabilometric Platform Test

Assessment of Functionality of Patients with Type IV Spinal Muscular Atrophy Treated with Spinraza: A Study with use of the Timed Up and Go Test, the Six-Minute Walk Test, the Hammersmith Functional Motor Scale, and Stabilometric Platform Test

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12626000157370
Enrollment
14
Registered
2026-02-06
Start date
2024-04-30
Completion date
2025-03-06
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of the study is to assess gait and fall risk in adults with type IV spinal muscular atrophy (SMA) who are being treated with Spinraza. Participants were evaluated using the following assessments: the Timed Up and Go test, the Six-Minute Walk Test, the Hammersmith Functional Motor Scale, and stabilometric platform analysis. The study seeks to determine whether treatment with Spinraza improves balance, mobility, and overall functional performance. We hypothesize that the therapy will enhance postural control and reduce fall risk. The findings of this project may contribute to the development of more tailored physiotherapy programs for individuals with SMA.

Interventions

Participants were taking Spinraza outside of the study. HFMSE, 6MWT and Stabilometric Platform Analysis were performed once per every 4 months. TUG was performed 3 times and the shortest time was considered the representative result. All patients were already undergoing treatment, and the observation period in the present study was 8 months. The assessments had a total duration ranging from 50 to 80 minutes. Functional assessments were carried out in the following order: 1. Hammersmith Functio

Participants were taking Spinraza outside of the study. HFMSE, 6MWT and Stabilometric Platform Analysis were performed once per every 4 months. TUG was performed 3 times and the shortest time was considered the representative result. All patients were already undergoing treatment, and the observation period in the present study was 8 months. The assessments had a total duration ranging from 50 to 80 minutes. Functional assessments were carried out in the following order: 1. Hammersmith Functional Motor Scale Expanded (HFMSE) 2. Six-Minute Walk Test (6MWT) 3. Timed Up and Go Test (TUG) 4. Stabilometric Platform Analysis Assessment Tools 1. Hammersmith Functional Motor Scale Expanded (HFMSE) The HFMSE was administered according to the official Procedure Manual. The scale includes 33 items, each scored from 0 to 2 points: 0 = unable to perform the task, 1 = partially completes the task, 2 = completes the task according to the instruction. The maximum score is 66 points. The test was conducted under standardized conditions in a hospital gymnasium. Each task was demonstrated by the examiner, and the patient was given one or two attempts. Testing duration ranged from 15 to 30 minutes, depending on the patient's functional level. The HFMSE assesses motor performance in lying, sitting, and standing positions, and includes tasks involving mobility and transfers. Equipment used: Physiotherapy examination table Gymnastic mat Stopwatch (iPhone 8 stopwatch) Staircase with handrail (minimum 4 steps) Procedure Manual – HFMSE Measuring tape and ruler 2. Six-Minute Walk Test (6MWT) The 6MWT was conducted under controlled hospital conditions, along a straight, uninterrupted, 25-meter course. The patient was instructed to walk (not run) as far as possible within 6 minutes. Time was measured with a stopwatch, and verbal cues regarding the remaining time were given. Patients were allowed to stop and rest if needed, but the clock was not paused. To track progress more precisely, distance covered was recorded at one-minute intervals. All tests were performed under identical conditions to minimize external influences. The course length followed American Thoracic Society (ATS) guidelines. Equipment used: Stopwatch (iPhone 8 stopwatch) Measuring tape Result recording form Two traffic cones marking the 25-meter distance Pulse oximeter Blood pressure monitor 3. Timed Up and Go Test (TUG) The TUG test assessed functional mobility through the following procedure: The patient sat in a chair with back support. On the command "start," the patient stood up, walked 3 meters, turned around, walked back, and sat down. Each patient performed 3 trials, timed in seconds. The shortest time was considered the representative result. All tests were conducted in identical conditions to ensure consistency and reliability. Equipment used: Chair with backrest (height: 46 cm, width: 47 cm, depth: 40 cm) Stopwatch (iPhone 8 stopwatch) Traffic cone marking the walking distance Measuring tape Assessment sheet for recording patient data, results, and observations Interpretation of results: <10 seconds: normal performance 10–20 seconds: increased fall risk 20 seconds: significant locomotor impairment, indicating reduced functional independence 4. Stabilometric Platform Assessment The balance assessment was conducted using a dual-plate stabilometric platform (Koordynacja), performing Romberg tests with eyes open and closed. Patients stood barefoot on the platform, arms alongside the body, for 30 seconds with eyes open, then repeated with eyes closed. The platform software analyzed center of pressure (CoP) sway and generated a report including: Parameters analyzed: Length of statokinesiogram Mean sway Maximum sway Mean velocity Sway area Length/Area ratio Mean frequency % time within 5mm radius circle Number of postural corrections Romberg ratio parameters: Sway length Sway area Mean velocity Length/Area ratio

Sponsors

Anastazja Sarna - University School of Physical Education in Kraków, al. Jana Pawla II 78, 31-571 Kraków
Lead SponsorIndividual

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Diagnosis of type IV spinal muscular atrophy (SMA), Ongoing treatment with Spinraza (nusinersen), Independent ambulation.

Exclusion criteria

Injuries potentially affecting test results that prevented participation in either the first or second assessment, Motor disabilities precluding gait testing, Cognitive impairment preventing understanding of instructions.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 19, 2026